<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101150042</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30118</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Cancer Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Cancer Res.</journal-id>
<journal-title-group>
<journal-title>Molecular cancer research : MCR</journal-title>
</journal-title-group>
<issn pub-type="ppub">1541-7786</issn>
<issn pub-type="epub">1557-3125</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31110157</article-id>
<article-id pub-id-type="pmc">6679739</article-id>
<article-id pub-id-type="doi">10.1158/1541-7786.MCR-18-1233</article-id>
<article-id pub-id-type="manuscript">NIHMS1530140</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dahl</surname>
<given-names>Erika S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buj</surname>
<given-names>Raquel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leon</surname>
<given-names>Kelly E.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Newell</surname>
<given-names>Jordan M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Imamura</surname>
<given-names>Yuka</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bitler</surname>
<given-names>Benjamin G.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snyder</surname>
<given-names>Nathaniel W.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aird</surname>
<given-names>Katherine M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Cellular &amp; Molecular Physiology, Penn State College of Medicine, Hershey, PA, USA</aff>
<aff id="A2"><label>2</label>Department of Pathology, Penn State College of Medicine, Hershey, PA, USA</aff>
<aff id="A3"><label>3</label>Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA</aff>
<aff id="A4"><label>4</label>Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.</aff>
<aff id="A5"><label>5</label>AJ Drexel Autism Institute, Drexel University, Philadelphia, PA, USA</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Authorsâ€™ Contributions</p>
<p id="P2">Conception and design: K.M. Aird and E.S. Dahl</p>
<p id="P3">Development of methodology: N.W. Snyder and Y. Imamura</p>
<p id="P4">Acquisition of data (acquired and managed patients, provided facilities, etc.): E.S. Dahl, R. Buj, K.E. Leon, J. M. Newell, Y. Imamura, B.G. Bitler, N.W. Snyder, K.M. Aird</p>
<p id="P5">Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Buj, E.S. Dahl, Y. Imamura, N.W. Snyder</p>
<p id="P6">Writing, review, and/or revision of the manuscript: E.S. Dahl, B. G. Bitler, N.W. Snyder, and K.M. Aird</p>
<p id="P7">Study supervision: B.G. Bitler, N.W. Snyder, and K.M. Aird</p>
</fn>
<corresp id="CR1"><label>*</label>Corresponding Author: Katherine M. Aird, Assistant Professor, Department of Cellular &amp; Molecular Physiology, Penn State College of Medicine, Hershey, PA, 717 531 5014, <email>kaird@psu.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P46">Disclosure of Potential Conflicts of Interest: The authors disclose no potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>17</volume>
<issue>8</issue>
<fpage>1710</fpage>
<lpage>1720</lpage>
<!--elocation-id from pubmed: 10.1158/1541-7786.MCR-18-1233-->
<abstract id="ABS1">
<p id="P8">Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer. High-grade serous carcinoma (HGSC) is the most frequently diagnosed and lethal histosubtype of EOC. A significant proportion of HGSC patients relapse with chemoresistant disease. Therefore, there is an urgent need for novel therapeutic strategies for HGSC. Metabolic reprogramming is a hallmark of cancer cells, and targeting metabolism for cancer therapy may be beneficial. Here, we found that in comparison to normal fallopian tube epithelial cells, HGSC cells preferentially utilize glucose in the TCA cycle and not for aerobic glycolysis. This correlated with universally increased TCA cycle enzyme expression in HGSC cells under adherent conditions. HGSC disseminates as tumor cell spheroids within the peritoneal cavity. We found that wildtype isocitrate dehydrogenase I (IDH1) is the only TCA cycle enzyme upregulated in both adherent and spheroid conditions and is associated with reduced progression-free survival. IDH1 protein expression is also increased in primary HGSC patient tumors. Pharmacological inhibition or knockdown of IDH1 decreased proliferation of multiple HGSC cell lines by inducing senescence. Mechanistically, suppression of IDH1 increased the repressive histone mark H3K9me2 at multiple E2F target gene loci, which led to decreased expression of these genes. Altogether, these data suggest that increased IDH1 activity is an important metabolic adaptation in HGSC and that targeting wildtype IDH1 in HGSC alters the repressive histone epigenetic landscape to induce senescence.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>